

# Keyword Index

- 10q24.32 . . . . . T156  
 22q11 . . . . . T37  
 4-Chlorokynurenine . . . . . W226  
 5-HT2A receptor . . . . . W196  
 5-HT2C . . . . . M130  
 5-HT3 receptors . . . . . W246  
 5-HT7 . . . . . M93  
 5C-CPT . . . . . W62  
 5HT5A receptor antagonist . . . . . W191  
 [11C]carfentanil . . . . . M143
- A**
- ABCB gene . . . . . W75  
 ABCB1 . . . . . T254  
 Abuse Liability . . . . . W160  
 Abuse Potential . . . . . W165  
 AC1 AC8 DKO . . . . . W268  
 accumbens . . . . . M74  
 acetylcholine . . . . . M82, M89, W214  
 acoustic startle . . . . . T246, W102  
 action . . . . . T45  
 activated microglia . . . . . T232  
 activation . . . . . W15  
 Acute Stress . . . . . M218  
 addiction . . . . . M139, M61, M75, M76, M107, M124,  
 M139, M201, M215, M244, M252,  
 T162, T168, T205, W1, W38, W173,  
 W218, W231, W233, W263, W266,  
 M48, M59, T81, W99, W131, W184,  
 W204, W219  
 adenosine triphosphate (ATP) . . . . . T27  
 ADHD . . . . . T86, M61, M169, T86,  
 T94, T154, T210, W128, W160,  
 W203, W92, M184  
 Adherence . . . . . T132  
 Adiponectin . . . . . W34  
 adjunctive . . . . . T83  
 ADNI . . . . . T158  
 Adolescence . . . . . M14, M34, M240, W99, M10,  
 M29, M151, M225, T45, W10, W51,  
 W205  
 Adolescent . . . . . M139, M167, M250, W33,  
 W83, M219, W42, W269, M51, M170,  
 T220, W136, M6, M163, W7, W82  
 Adolescent binge drinking . . . . . T15  
 Adolescent Depression . . . . . M198  
 adolescent development . . . . . M100, W223, M133  
 adolescent stress . . . . . M21  
 ADRA1A . . . . . T262  
 adrenergic receptor . . . . . W205  
 adult . . . . . W82  
 Adversity . . . . . M199  
 aerobic . . . . . M163  
 affective disorders . . . . . W80  
 affective neuroscience . . . . . M167  
 affective priming . . . . . M112  
 African American . . . . . T197  
 aggression . . . . . M78, M211, T154, W74  
 aging . . . . . W31, M181, M223, T54, W30, W31, W227,  
 M141, M156, M232, W5, W104  
 Agomelatine . . . . . W210  
 Agonist . . . . . M266  
 agoraphobia . . . . . T248  
 Akt . . . . . M8  
 AKT1 gene . . . . . W162  
 Alcohol . . . . . M14, M209, T52, T228, M16, M57,  
 M63, M71, M243, T76, T168, T264,  
 W44, W59, W205, W265  
 alcohol abuse . . . . . T261, W218  
 Alcohol consumption . . . . . T212  
 Alcohol dependence . . . . . W171, W72, W178  
 alcohol disorder . . . . . M264  
 alcohol exposure . . . . . M51  
 Alcohol intake . . . . . W180  
 Alcohol preferring P rats . . . . . T228  
 alcohol use disorder . . . . . M127, W85  
 Alcohol-seeking behavior . . . . . T263  
 Alcoholism . . . . . W37, T200, W37, W194, M55  
 Aldehyde . . . . . W230  
 ALFF . . . . . M174  
 ALK . . . . . M83  
 ALKS 5461 . . . . . W189  
 Allosteric . . . . . M266  
 allosteric modulator . . . . . W186  
 alpha . . . . . W71  
 alpha-7 nicotinic acetylcholine receptor . . . . . W208  
 alternative medicine . . . . . T74  
 alternative splicing . . . . . T174  
 Alzheimer's . . . . . T43, T73, T77, T122, T161, T216  
 AMPA . . . . . T32, T256

AMPA antagonist . . . . . T16  
 ampa receptor . . . . . T27  
 AMPAR . . . . . T38  
 Amphetamine . . . . . M49, M103, W186  
 Amygdala . . . . . M70, M94, T15, T42, W22, W117, W232,  
     W249, T13, M16, M42, M62, M105,  
     M144, M168, M172, M236, T13, T248,  
     W7, W95, W243  
 Amyloid . . . . . T158  
 analgesia . . . . . M87, T269  
 anatomical connectivity . . . . . W168  
 anger . . . . . W38  
 anhedonia . . . . . M86, W14, W216, W224  
 animal model . . . . . M6, M25, M27, M75, T18, T46,  
     W182, W224  
 ANK3 . . . . . T167  
 anorexia nervosa . . . . . M105, M237, T227, W126,  
     W217, W166, M142  
 anterior cingulate . . . . . M146  
 anterior cingulate cortex . . . . . W41, W115  
 Antidepressant . . . . . M46, T68, T106, T115, T127,  
     T221, W213, W269, T133, T58, T133,  
     W12, W157, W221, M195, T17,  
     T66, T145, W75, W127, W185,  
     W221, W254, T149, T152  
 Antidepressant 5. Amygdala reactivity . . . . . M207  
 antidepressant response . . . . . T254  
 Antipsychotic . . . . . M192, M200, T116, T123, T137, T150,  
     M43, T119, T132, T176, T196, T244,  
     T246, W196, T188, T206, W93  
 Antipsychotic agents . . . . . T138, W6  
 antipsychotic medication . . . . . M208, W20  
 Antipsychotic monotherapy . . . . . M106  
 Antipsychotic response . . . . . T203  
 Antipsychotic-naïve first-episode schizophrenia . . . . . M106  
 antisense transcription . . . . . T184  
 antisocial personality disorder . . . . . M136  
 Anxiety . . . . . M268, M8, M121, M180, M207, M268,  
     T15, T200, T223, T248, T249, W23,  
     W209, W232, M267, M31, M62, M79,  
     M80, M113, M262, M267, T36, T178,  
     W14, W17, W132, W166, W253  
 anxiety disorders . . . . . M185, T92  
 APOE . . . . . M102, M102, M156  
 appetite . . . . . M147  
 Arc . . . . . T1  
 area 25 . . . . . W18  
 aripiprazole . . . . . T90, T125, T129  
 aripiprazole lauroxil . . . . . T104  
 aromatase . . . . . M256  
 AS3MT . . . . . T156  
 ASD . . . . . M23, T109

ASP0777 . . . . . W213  
 Association . . . . . W22  
 associative learning . . . . . W237  
 Astrocyte . . . . . T10, T23, T40, T44  
 astroglia . . . . . W116  
 Asymptomatic Status . . . . . W164  
 Attachment . . . . . M229  
 Attention . . . . . M269, W42, W110, W216, M254, W45, W77  
 attentional bias . . . . . W67, W266  
 attribution . . . . . W36  
 atypical antipsychotic drug . . . . . M82, T180, T148, T250  
 Auditory . . . . . W251  
 Auditory hallucinations . . . . . W66  
 auditory processing . . . . . W71, W151  
 augmentation . . . . . T83, T92  
 Autism . . . . . M42, M239, M23, M33, M40, M161, M259, T10,  
     T19, T174, W50, W188, W195, W248  
 autism spectrum disorder . . . . . M15, T124, T109, W172, W215  
 autobiographical memory . . . . . M144  
 Autoimmune encephalitis . . . . . M265  
 autoimmunity . . . . . M53  
 aversion . . . . . W258  
 Axotomy . . . . . T55  
 AZD6765 . . . . . W192

**B**

baby-cry . . . . . W79  
 baclofen . . . . . T76  
 Balb/c mouse . . . . . M40  
 Basal Ganglia . . . . . W262, M191, W231  
 Basimglurant . . . . . T127  
 basolateral amygdala . . . . . W158  
 bath salts . . . . . M115  
 Bayesian . . . . . T70  
 Bayesian inference . . . . . W66  
 BDNF . . . . . M26, T1, T16, T33, T45, W13, W21  
 bed nucleus of the stria terminalis . . . . . T39  
 Behavior . . . . . M34, W194, W59  
 behavior predictor . . . . . W26  
 behavioral . . . . . M23  
 behavioral despair . . . . . W97  
 behavioral flexibility . . . . . W61  
 Behavioral Pharmacology . . . . . W225  
 benzodiazepine . . . . . M127  
 beta oscillations . . . . . W239  
 bi-polar depression . . . . . T88  
 binge drinking . . . . . M83, W115  
 Binge eating . . . . . M48, W187

- Binge-eating disorder . . . . . M12  
 Bioenergetics . . . . . W124, W242  
 biological marker . . . . . T252  
 Biomarker . . . . . M109, T122, W129, W157, W172, M217,  
     T146, T215, W75, W121, W239, T50,  
     W235, W259, T223, W84  
 Biomarker risk assignment algorithm . . . . . T79  
 Biotype . . . . . M241  
 bipolar . . . . . M163, M250, M255, T87, T196, W182, W235  
 bipolar depression . . . . . T69, T144, T120  
 Bipolar Disorder . . . . . M109, M226, M176, M231, W52,  
     W146, M39, M162, M175, M185,  
     M224, M235, M264, T14, T35,  
     T131, T182, T189, T205, T208, W45,  
     W73, W92, W94, W141, W142, W202,  
     T250, W35, W156  
 Bipolar I Depression . . . . . T135, W4  
 Birth Outcomes . . . . . W169  
 Bitopertin . . . . . T121  
 blood . . . . . T172  
 blood-brain correlations . . . . . M263  
 BNST . . . . . M267  
 body dysmorphic disorder . . . . . M105, W126  
 body weight . . . . . W217  
 BOLD . . . . . W128  
 Borderline Personality . . . . . T239, M133, W39  
 BPAD . . . . . T20  
 Brain . . . . . M239, W70, W79  
 brain activation . . . . . M211  
 Brain Anatomy . . . . . M221  
 brain connectivity . . . . . M110, M208  
 Brain development . . . . . M199, T213, M96, M96  
 brain imaging . . . . . M114, M177, T232, W55  
 Brain neurotrophic factor . . . . . T41  
 brain stimulation . . . . . M252, W16, W133, W143, W149  
 Brain Stress . . . . . W242  
 brain volume . . . . . W51, W25  
 Brain-Derived Neurotrophic Factor . . . . . W25  
 BrdU . . . . . M30  
 Brexpiprazole . . . . . T100, W3, T101  
 Brodmann area 25 . . . . . M217, M94  
 bulimia nervosa . . . . . M237  
 Buprenorphine . . . . . W189, W209, T245  
 Buprenorphine-Naloxone . . . . . T71  
 bupropion . . . . . M68, W184
- C**
- c-Fos . . . . . T31  
 CACNA1C . . . . . T167  
 calbindin . . . . . W112  
 calcium . . . . . T35  
 calcium imaging . . . . . W241  
 calcium-permeable AMPA receptors . . . . . M74  
 calretinin . . . . . W112  
 calsyntenin . . . . . T8  
 canine adenovirus . . . . . T230  
 cannabinoid . . . . . M31, M85, M148, T236, T253, T269, W190  
 cannabis . . . . . M104, M140, M223, T218, T236, W137,  
     W197, W120, T209, T269, W120,  
     W155  
 Cannabis Dependence . . . . . W238  
 cannabis use . . . . . M100  
 CANTAB . . . . . T105  
 Cardiometabolic Risk . . . . . T150  
 cardiovascular . . . . . M80  
 Cardiovascular disorders . . . . . T238  
 cariprazine . . . . . M28, M43, T69, T84, T93, T95  
 Carisbamate . . . . . W178  
 carvedilol . . . . . T247  
 catecholamine . . . . . T161, T180, W187  
 categorical . . . . . M123  
 CB1 . . . . . M31  
 CB1 receptor . . . . . M113  
 CBT . . . . . M214  
 CD11b antibody . . . . . T232  
 CD44 . . . . . W117  
 Cdk5 . . . . . T57  
 Cell adhesion molecule . . . . . W218, W219  
 Centanafadine . . . . . W160  
 Centanafadine SR . . . . . T94  
 central nucleus of the amygdala . . . . . M69  
 cerebellum . . . . . M134, M161, M206, T168, M20  
 Cerebral Blood Flow . . . . . M232  
 cerebral folate deficiency . . . . . W152  
 cerebrospinal fluid . . . . . T183, T53  
 chemokine . . . . . T146  
 Child abuse and neglect . . . . . M114  
 Child Behavior Checklist . . . . . T162  
 child offspring . . . . . M235  
 childhood maltreatment . . . . . M258  
 Childhood Onset Bipolar Disorder . . . . . T173  
 Childhood trauma . . . . . T212, T163  
 Childhood-onset schizophrenia . . . . . M149  
 Children and Adolescents . . . . . M169, M219  
 Chinese . . . . . T189  
 choice . . . . . M63  
 cholecystikinin receptors . . . . . T201  
 chondroitin sulfated proteoglycans . . . . . W108



- CYP2A6 genotype . . . . . W252  
 cytokine . . . . . M71, T206, W224, W109,  
 T64, M1, T56, T64, W8, W89
- D**
- D-amino acid oxidase . . . . . W211  
 d-cycloserine . . . . . W40  
 D-serine . . . . . T47, W211  
 D1 agonist. . . . . T234  
 D2 receptor . . . . . M98, M67T202  
 D3 receptor . . . . . W196  
 dACC . . . . . M193  
 dACG . . . . . M225  
 DAMPs . . . . . W156  
 DAT/NET inhibition . . . . . T86  
 Data mediation and integration . . . . . W154  
 DBS . . . . . W133, W150  
 decision . . . . . M209  
 Decision Making . . . . . T255, W261, W68, M2, W10  
 declarative memory . . . . . W48  
 deep brain stimulation . . . . . M33, T228, W131  
 deep sequencing . . . . . T187  
 default mode network . . . . . M122, M140, M184, W29  
 default network . . . . . M216  
 delay discounting. . . . . W60, W203  
 Dementia. . . . . T73  
 dendrites . . . . . T16  
 dendritic remodeling . . . . . W34  
 Dendritic Spine . . . . . T5, T9, M32, T214  
 dentate . . . . . W43  
 dentate gyrus. . . . . T54, W34  
 dependence . . . . . T262, W197  
 Depression . . . . . M268, M1, M7, M8, M19, M45, M46,  
 M108, M110, M182, M207, M214,  
 M231, M234, M247, M257, M268, T58,  
 T106, T113, T115, T134, T139, T142,  
 T143, T164, T216, T223, T249, T265,  
 W12, W29, W52, W63, W91, W109,  
 W118, W157, W179, W209, W226,  
 W269, T194, M6, M39, M44, M65,  
 M66, M72, M75, M79, M80, M84,  
 M86, M89, M91, M135, M138, M144,  
 M147, M157, M181, M190, M217,  
 M258, M261, M270, T4, T22, T42,  
 T45, T46, T50, T56, T63, T87, T95,  
 T102, T112, T145, T149, T178, T187,  
 T194, T215, T235, T270, W7, W24,  
 W33, W51, W76, W125, W127, W130,  
 W132, W135, W142, W152, W161,  
 W175, W176, W182  
 depressive symptoms . . . . . W113  
 deprivation . . . . . T264  
 Devaluation . . . . . W180  
 development . . . . . M193, W10, W245, W253, M119  
 Developmental. . . . . W47  
 Developmental Psychopathology. . . . . M91  
 developmental trajectories . . . . . W90  
 diabetes. . . . . M190, T148  
 diagnostic criteria . . . . . T147  
 Dieting . . . . . M159  
 diffusion . . . . . M128  
 diffusion spectrum imaging . . . . . M120  
 Diffusion tensor imaging . . . . . M106, M183, M249, T53,  
 M120, M228, T217  
 Diffusion Weighted Imaging. . . . . M166  
 dimensional. . . . . M123  
 dimensions of psychosis. . . . . T141  
 Direct pathway . . . . . W234  
 Disability. . . . . T106  
 DISC1 . . . . . M245  
 disinhibition . . . . . W45  
 Distress intolerance . . . . . W174  
 DLPFC . . . . . T213  
 DNA Methylation. . . . . W104, M79, T15, T172  
 domesticate . . . . . M78  
 Dopamine . . . . . W120, M98, M14, M180, M200,  
 M266, W110, W120, W123, W230,  
 W264, M2, M11, M12, M18, M21, M22,  
 M28, M38, M43, M67, M68, M83,  
 M124, M150, M165, M230, T69, T84,  
 T93, T95, T155, T234, T235, W15, W61,  
 W145, W162, W191, W214, W224,  
 W228, W233, W237, W257, W264  
 Dopamine 2 Receptor . . . . . W222  
 dopamine circuitry . . . . . M191  
 dopamine D2 receptors . . . . . M197  
 dopamine D3 receptors . . . . . T16  
 Dopamine receptors. . . . . T203  
 dopamine release. . . . . M238  
 dopamine transporter . . . . . W186  
 dopamine uptake. . . . . M52  
 dopamine-1 receptor . . . . . T118  
 Dorsal Attention Network . . . . . M173  
 dorsal raphe . . . . . M44  
 dorsolateral prefrontal cortex . . . . . T266  
 Dose occupancy. . . . . M153  
 dose reduction. . . . . T137  
 DRD2 gene expression . . . . . T203  
 DRD2 locus. . . . . T202  
 DREADD. . . . . T21, T44, W58  
 DREADD Receptor. . . . . M20

drug abuse . . . . . W98, T241  
 drug conditioning . . . . . T57  
 drug prime . . . . . W247  
 drug target . . . . . T176  
 drugs . . . . . T198  
 DSM . . . . . M241  
 DSM-5 . . . . . T141, T147  
 DTI . . . . . M131, M175  
 Duplicate subject . . . . . T75  
 Dynorphin . . . . . W232, W258  
 Dysregulation . . . . . M219

## E

early improvement . . . . . T131  
 Early life stress . . . . . W171, W70, W95  
 Early Phase Drug Development . . . . . T96  
 early psychosis . . . . . W74  
 eating . . . . . M130, M159  
 Eating disorders . . . . . M48, T51, T3, W36, W60  
 ecological momentary assessment . . . . . T225  
 ECT . . . . . M84, M234, W129, W138  
 education . . . . . M270  
 educational attainment . . . . . T207  
 EEG . . . . . M4, M182, W46, W56, W73, W78, W84,  
 W133, W138, W245  
 EEG biomarkers . . . . . M101  
 Effect Size . . . . . T153  
 efficacy . . . . . T104, W4  
 Efficacy and safety . . . . . W3  
 Effort . . . . . M152  
 elderly . . . . . M165  
 electroconvulsive . . . . . M33  
 electroconvulsive therapy . . . . . W130, W135, W140  
 electrophysiology . . . . . M54, T19, T140, W208,  
 W249, W234  
 Ellis-van Creveld . . . . . T20  
 emotion . . . . . M148, M172, W70  
 Emotion Modulation . . . . . M218  
 Emotion Perception . . . . . W68  
 emotion processing . . . . . M168, M231  
 Emotion Recognition . . . . . W22, W172  
 emotion regulation . . . . . W24  
 emotional arousal . . . . . M211  
 Emotional Eating . . . . . T164  
 emotional processing . . . . . T85  
 emotional reactivity . . . . . W67  
 empathy . . . . . W79  
 encoding . . . . . W44

endocannabinoid . . . . . M77, W207, W255, W256  
 endogenous opioids . . . . . M143  
 endophenotype . . . . . M101, M241, W73, M182, W54  
 endoplasmic reticulum . . . . . T48  
 endotoxin . . . . . W113  
 energy homeostasis . . . . . T3  
 environment . . . . . T225  
 epidemiology . . . . . W88  
 Epigenetic . . . . . M199, T160, M21, M41, M50,  
 M263, T7, T61, T205, T41, T64, T64  
 episodic memory . . . . . W48  
 eQTL . . . . . T157, T157  
 ErbB4 pathway . . . . . T34  
 ERP . . . . . W38, W81  
 errors . . . . . M193  
 escitalopram . . . . . T83  
 estradiol . . . . . W31, M261, M262, W27, W31, M240  
 estrogen receptor . . . . . T72  
 estrous . . . . . W257  
 ethanol . . . . . M10, M70, T220, W204, W219  
 ethics . . . . . W141  
 event related potentials . . . . . T201, W150, W28  
 excitability . . . . . T62  
 Excitatory Synapses . . . . . T2  
 executive function . . . . . M224, W21, W76, W53  
 exercise . . . . . W125, T78  
 exome scan . . . . . T201  
 exome sequencing . . . . . T165  
 expectation . . . . . M118  
 Exposure therapy . . . . . T99  
 expression . . . . . W107  
 externalizing disorders . . . . . T162  
 Extinction . . . . . M125, W123, M54, T99, T248  
 Extinction learning . . . . . W37  
 Extinction Memory Recall . . . . . M242  
 extracellular matrix . . . . . M97

## F

FAAH . . . . . T200, T242  
 FAAH inhibitor . . . . . M153  
 face emotion . . . . . M112  
 facial emotional processing . . . . . M167  
 familial aggregation . . . . . W92  
 Familial Loading . . . . . T173  
 familial risk . . . . . M128, W72  
 familiarity . . . . . W90  
 fat . . . . . T264  
 fatty acid . . . . . T51, W144



- fear . . . . . T13, M24, M62, T13, T154, M125, M189  
 Fear conditioning . . . . . W123, T64, T257, W17  
 Fear extinction . . . . . M121, M262, W257, W23  
 fear generalization . . . . . W243  
 fear processing . . . . . M105  
 fear-odor circuit . . . . . M178  
 FEAST . . . . . W138  
 Feedback Inhibition . . . . . M9  
 feeding . . . . . M36  
 female . . . . . M255, W175  
 fetal alcohol syndrome . . . . . T4  
 first episode . . . . . M104, T244  
 FKBP5 . . . . . M259, T49, T163, T164  
 fMRI . . . . . W31, M102, M100, M102, M108, M110, M112,  
 M121, M123, M125, M127, M129, M130,  
 M132, M133, M144, M146, M147, M151,  
 M152, M170, M175, M176, M177, M181,  
 M188, M189, M195, M197, M210,  
 M215, M216, M218, M220, M224,  
 M229, M231, M242, T160, T255, W9,  
 W19, W24, W31, W42, W47, W49,  
 W50, W60, W65, W77, W80, W140,  
 W142, W147, W161, W249, W253,  
 M187  
 fMRI Functional Connectivity . . . . . W122  
 fMRI/imaging genetics . . . . . M160  
 Food deprivation . . . . . W180  
 food intake . . . . . W217  
 food preferences . . . . . W147  
 forced swim test . . . . . M89, W201  
 fox . . . . . M78  
 Fractional-anisotropy . . . . . M137  
 free water . . . . . M213  
 frontal cortical . . . . . M51  
 fronto-striatal networks . . . . . T202  
 function . . . . . T231  
 functional . . . . . M222  
 Functional capacity . . . . . W5  
 functional connectivity . . . . . M115, M195, M204, M250, W252,  
 M158, W29  
 functional magnetic resonance imaging . . . . . M167  
 functional neuroimaging . . . . . T180  
 functional organization . . . . . M194  
 functional outcome . . . . . W145  
 Functional Selectivity . . . . . W222  
 Functioning . . . . . T143, T125
- G**
- G protein . . . . . T50  
 GABA . . . . . M98, M116, M117, T24,  
 T26, T140, W119, W125, W191,  
 W195, W231, W106  
 GABAA . . . . . T36  
 GABAB . . . . . T76  
 GABAergic boutons . . . . . W112  
 GABAergic cells . . . . . M60  
 GABAergic interneurons . . . . . W236  
 GABRA2 . . . . . T162  
 GAD . . . . . T74, W112  
 galanin . . . . . T178  
 gambling . . . . . W18  
 gamma oscillation . . . . . M104, T234, W236, W28,  
 W238, W56, W239  
 gender . . . . . T237  
 gene association . . . . . T177  
 Gene environment interaction . . . . . T212  
 gene expression . . . . . T157, T266, M96, M69,  
 M96, T66, T157, T166, T172,  
 T177, T193, T266, W183  
 Gene manipulation . . . . . T230  
 Gene X smoking status . . . . . W252  
 Generalizability . . . . . T219  
 generalized anxiety disorder . . . . . T82  
 genetic . . . . . T154, T158, T268, W37, T6,  
 T161, T168, T170, T180, T185,  
 T198, T207, W37, T153,  
 T159, T173  
 genetic ancestry . . . . . T197  
 genetic modeling . . . . . T227  
 genetic mouse model . . . . . M42  
 genome-wide association study . . . . . T169, T182, W98,  
 W159  
 Genomic . . . . . W129  
 geriatric . . . . . M110, W52  
 gestational age . . . . . M183  
 Ghrelin . . . . . W194  
 glia . . . . . T10  
 Globus Pallidus . . . . . W262  
 GLT-1 . . . . . T32  
 glucocorticoid . . . . . M21, M259, M263  
 glucocorticoid receptor . . . . . M260, T66  
 glucocorticoid receptor gene . . . . . T195  
 glutamate . . . . . M208, T30, T32, T40, T67, T205, T231,  
 W28, W59, W106, W114, W125,  
 W263, M141, M198, T175, T220,  
 W118, W189  
 glutamate GABA . . . . . W268  
 glutamate receptor activity . . . . . T169  
 glutamate/glutamine cycle . . . . . M56  
 Glutamine . . . . . M198

glutathione . . . . . M213  
 glycine . . . . . T47  
 glycine transporter 1 . . . . . M40  
 GLYX-13 . . . . . T68  
 Golgi-Cox . . . . . M30  
 Gonadal Hormones . . . . . T265  
 GPCR . . . . . T50  
 GR chaperone . . . . . T49  
 graph . . . . . M222  
 graph theory . . . . . W70, W126  
 Graph-based Analysis. . . . . M210  
 GRM3 . . . . . T184  
 GSTT2. . . . . T23  
 guanfacine. . . . . T210, T253  
 guanfacine . . . . . W203  
 Gut Microbiome . . . . . T223, M268  
 GWAS. . . . . T157, T170, T176, T186,  
 T190, T207, W96, W101

## H

habit . . . . . W59  
 habituation . . . . . M171  
 hallucination . . . . . W77  
 hallucinogen . . . . . M90, M229  
 HAM-D. . . . . T113  
 HAND. . . . . M52  
 Hawthorne effect . . . . . T103  
 HDAC. . . . . M50, T49, T268  
 HDAC inhibitors . . . . . W202  
 health promotion. . . . . T226  
 heart rate variability . . . . . W240  
 heritability. . . . . T204  
 Heroin . . . . . T241, W131  
 heroin self-administration . . . . . M11  
 high risk . . . . . M139, M176  
 High throughput screening. . . . . W2  
 high-resolution . . . . . M223  
 Hippocampal volume. . . . . M227  
 Hippocampus . . . . . M94, W100, M24, M84, M126,  
 M134, M223, T11, T12, T231,  
 T237, W27, W43, W83, W241  
 hippocampus-mPFC pathway . . . . . T21  
 hIPSCs . . . . . T37  
 Histone . . . . . T41  
 HIV . . . . . T71, T171, W91, W240  
 HIV-1 . . . . . M52  
 Hoarding Disorder. . . . . T151  
 homer . . . . . W1

hostility. . . . . T130  
 HPA . . . . . M92  
 HPA axis. . . . . M258  
 human laboratory . . . . . T243  
 Human Neuroimaging . . . . . M247  
 humans. . . . . T260  
 hunger . . . . . W255  
 hyperalgesia . . . . . M37  
 Hypnosis. . . . . W9  
 hypothalamic-pituitary-adrenal axis . . . . . M253  
 hypothalamus . . . . . M37, T39

## I

ICD. . . . . T113  
 ICD Shocks . . . . . T113  
 imaging. . . . . M107, M145, M203, M230, W11, W127,  
 M155, M164, M201, M209,  
 M219, M229, M232  
 imaging genetics . . . . . T177  
 Immune . . . . . T23, W103, W250  
 immune system . . . . . W260  
 immunity . . . . . W229  
 implicit priming . . . . . W147  
 impulsivity . . . . . M129, M136, T61, W203, W228  
 In vitro neuronal differentiation . . . . . W2  
 in vivo . . . . . W241  
 inactivation. . . . . W247  
 incentive motivation . . . . . W180  
 incentive salience. . . . . M25, W263  
 inclusion and exclusion . . . . . W81  
 incubation. . . . . M47  
 individual differences. . . . . M220  
 Induced pluripotent stem cells (iPSCs) . . . . . T185, W2  
 infant . . . . . W8  
 inflammation. . . . . M26, M81, M213, T259, W200,  
 W229, W235, M45, M141, M227,  
 M232, M251, T171, W156  
 Inflammatory Markers . . . . . W109  
 informatics . . . . . W250  
 Information-Processing Biases . . . . . W42  
 infralimbic cortex . . . . . M262  
 inhibition . . . . . T43  
 inhibitory synaptic transmission. . . . . M36  
 Insight . . . . . W149  
 insomnia. . . . . T70  
 Insula . . . . . M209, M225, W32  
 Insula Connectivity . . . . . M142  
 insulin . . . . . T196





MCP-1/CCL2 . . . . . T171  
MDD . . . . . M174, M246  
MDMA . . . . . T255, T260, W105  
MDPV . . . . . M115  
mecamylamine . . . . . M216  
MeCP2 . . . . . W192  
Medial Prefrontal Cortex . . . . . M158, W179, W246  
Medication Development . . . . . W184  
medio-dorsal thalamus . . . . . M13  
meditation . . . . . T126, W244  
Medium Spiny Neuron . . . . . T5, T33  
MEG . . . . . W57  
mega analysis . . . . . W154, W154  
MEI . . . . . T80  
melanocortin . . . . . M16  
Melatonin . . . . . T59, W139  
Memory . . . . . W99, T64, M64, M171, T256, T257, W44, W58  
Memory Consolidation and Extinction . . . . . W210  
memory reconsolidation . . . . . T30  
menopause . . . . . W27  
Mentalizing . . . . . W39  
MEPS . . . . . W93  
meta-analysis . . . . . M162, T188, T190, W89, T92, T134  
metabolic syndrome . . . . . W94  
metabolism . . . . . T194  
metabolomics . . . . . W144, T51  
Metadoxine . . . . . W128  
metformin . . . . . T148  
Meth . . . . . T44  
Methadone . . . . . T71  
Methamphetamine . . . . . W184, M205, W58,  
W67, W96, W220, W240  
methods . . . . . W50  
methylation . . . . . T195, T196, T211  
methylphenidate . . . . . M85, M118, T210  
metyrapone . . . . . T258  
mGlu 2/3 . . . . . W181  
mGlu2/3 receptor . . . . . W185  
mGlu5-NAM . . . . . T127  
mice . . . . . M4  
micro-array . . . . . M1  
microglia . . . . . M60, T63, W111, W116, T23  
microglial activation . . . . . M22  
microPET . . . . . M201  
MicroRNA . . . . . M59, T183  
midbrain . . . . . M11  
mild cognitive impairment due to AD . . . . . T79  
military . . . . . W86, T170, W86  
Milnacipran . . . . . T109

mindfulness . . . . . T126  
mineral corticoid receptor . . . . . M260  
Minor Tobacco Alkaloids . . . . . W225  
miR132 . . . . . T1  
miRNA . . . . . M45, W107  
mirror neuron system . . . . . W78  
Mitochondria . . . . . W242, W176  
monkey . . . . . W56, W220  
monoamine depletion . . . . . W110, M46  
monoamine oxidase . . . . . M154, M256  
monoamine oxidase A . . . . . M136  
monoamines . . . . . M154  
Montgomery-Asberg Depression Rating Scale . . . . . T103  
Mood . . . . . W155, T260  
mood disorder . . . . . M212, W89, W173, T20,  
T142, W136, T238, T66, T226  
mood dysregulation . . . . . M138  
morphine . . . . . M18, T12  
morphine-like opioids . . . . . M87  
morphological and resting state brain activity . . . . . W260  
morphology . . . . . M107, W82  
morphometry . . . . . M76, T22  
motivated drug taking . . . . . T267  
motivation . . . . . M67, T38, W79, M141, M152, T2, W101  
motor activity . . . . . W45  
motor behavior . . . . . M5  
mouse . . . . . M1, M15, M53, M60  
mouse brain . . . . . T224  
mouse model . . . . . M61, M81, W98, W222  
movement disorders . . . . . W150  
MR imaging . . . . . M55  
MR spectroscopy . . . . . M55  
MRI . . . . . M76, M156, M178  
mRNA . . . . . T185  
MRS . . . . . M146, M248, T231, W114, W119  
mTOR . . . . . M65  
mu suppression . . . . . W78  
mu-opioid receptors . . . . . T24  
multisensory . . . . . W57  
multivariate . . . . . M202  
muscarinic acetylcholine receptor . . . . . W198  
myelin imaging . . . . . M134  
myoinositol . . . . . W116

## N

N-acetylaspartate . . . . . M137  
N-acetylcysteine . . . . . T108, M151, M3  
N-glycosylation . . . . . T48

- N-methyl-D-aspartate. . . . . T121  
 NAcore . . . . . T44  
 Naltrexone. . . . . T251  
 negative emotionality. . . . . W38  
 Negative Symptom Factor . . . . . T116  
 Negative Symptoms . . . . . M152, T222, T98, W198  
 network. . . . . W250  
 network metrics. . . . . W168  
 neural circuits . . . . . T224, T10  
 neural plasticity. . . . . W140  
 neural stem cell . . . . . T4  
 neuregulin-1 . . . . . M183  
 neurexin . . . . . M23, T8  
 neuritogenesis . . . . . W201  
 neuroanatomy . . . . . M233  
 neurocircuitry . . . . . M172, W267  
 neurocognition . . . . . T145, W64, W75, M103, W25  
 neurodegeneration. . . . . M145, T217, T54  
 neurodevelopment . . . . . M26, M79, T14, T19, T227, W124  
 neuroeconomic . . . . . W36  
 Neuroendocrine. . . . . M34  
 Neuroepithelium . . . . . T59  
 Neurogenesis . . . . . T96, M84, T17  
 Neurogenesis enhancers . . . . . T133  
 neurogenic niche . . . . . T60  
 neuroimaging . . . . . M69, M117, M162, M179,  
     M186, M212, M226, M261,  
     W76, M119, M149, M240, W12  
 neuroimmune . . . . . T17, M265  
 neuroimmune interaction. . . . . M264  
 Neuroimmunology. . . . . W163  
 neuroinflammation . . . . . M157, M196, T217, W111,  
     W115, W116, W175  
 neuroinformatics . . . . . W154  
 neuroligin . . . . . T26  
 Neurological disorders . . . . . T238  
 Neuromodulation. . . . . W143, W133, W134  
 neuronal maturation . . . . . W95  
 Neuronal stem cells (NSCs) . . . . . W2  
 neuronal tracing . . . . . T39  
 neuropathic pain . . . . . T114  
 neuropeptides . . . . . T267  
 Neuropil . . . . . W124  
 Neuroplasticity . . . . . W129, T54, T108, W148  
 neuroprogression. . . . . M235  
 neuropsychology . . . . . M220, W130  
 neuroreceptor . . . . . M230  
 Neuroserpin . . . . . T65  
 Neurospheres . . . . . T59  
 neutral cb1 . . . . . M77  
 NF kappa B. . . . . T52  
 NG2 . . . . . W108  
 nicotine. . . . . M102, M41, M77, M215,  
     M216, T243, T258, W88, W214,  
     M158, M3, T76, T81, W99, W100,  
     W219  
 nicotine addiction . . . . . W21, W225  
 nicotine dependence . . . . . T197  
 nicotinic acetylcholine receptors. . . . . T42  
 nicotinic receptor . . . . . W214  
 Nitrous Oxide . . . . . T142  
 NMDA . . . . . T266, M29, T47, T87, T266, W211  
 NMDA Antagonists . . . . . W192  
 NMDA channel blocker . . . . . W213  
 NMDA glycine-site receptor . . . . . W226  
 NMDA Receptor . . . . . T68, W179, M56, W40, W227, T27  
 NMDA receptors . . . . . W206, W236  
 nociceptin . . . . . T85  
 non-human primate. . . . . M22, M94  
 Non-Pharmacological Therapy . . . . . W146  
 noncoding RNA. . . . . T191  
 nonhuman primate model . . . . . M91  
 Nonhuman Primates . . . . . W225  
 NOP agonists. . . . . M87  
 NOP receptor antagonist . . . . . T85  
 NOR . . . . . M93  
 noradrenergic . . . . . M88, M111, T107  
 Noradrenergic System . . . . . T109  
 norepinephrine . . . . . T235  
 novel object recognition. . . . . M82  
 NPAS2 . . . . . T36  
 Nucleus Accumbens. . . . . M7, T18, T38, T228,  
     W234, W131, W258, W264,  
     M11, M17, M32, M67, M187,  
     T62, W199, W258, W264  
 Nucleus Accumbens Shell. . . . . T29  
 nucleus reuniens . . . . . W241
- O**
- Obesity . . . . . W94, T38, W147, W168  
 Obsessive Compulsive Disorder . . . . . M146, T175, T229,  
     W87, W134, W163, M179, M193,  
     M248, M265  
 obstetric complications . . . . . T186  
 odor cue . . . . . M178  
 ODZ4 . . . . . T167  
 older adults. . . . . T88  
 Olfaction. . . . . W172, M186, W14

omega-3 . . . . . W144, W235  
 Omega-3 Fatty Acid . . . . . M176  
 omega-6 . . . . . W144  
 omics . . . . . T161  
 ondansetron . . . . . T98  
 operant antinociception . . . . . M87  
 opiates . . . . . T9  
 opioid . . . . . M12, M135, T245, W190, W268, W174, M72  
 opioid neurotransmission . . . . . M160  
 Opioid system . . . . . T251  
 OPRM1 A118G . . . . . T153  
 optogenetics . . . . . M13, M54, T21, T229, W158, W243  
 orbitofrontal . . . . . T187  
 orbitofrontal cortex . . . . . T229, W261, M36  
 orexin . . . . . T70  
 orexin receptor antagonist . . . . . T114  
 oscillation . . . . . W16  
 ouabain . . . . . M39  
 oxazepam . . . . . T258  
 oxidative stress . . . . . M154, M196  
 oxytocin . . . . . M187, T155, T257, T261, W46,  
 W78, W207, M125, W193, W212

## P

P300 . . . . . W54  
 p38 MAPK . . . . . W215  
 P50 . . . . . T204, W8  
 PACAP . . . . . T3, W216  
 pachyman . . . . . T63  
 Pain . . . . . M201, M16  
 paliperidone palmitate . . . . . T110  
 Paliperidone palmitate once-monthly . . . . . T111  
 PANDAS . . . . . M265  
 panic . . . . . W166  
 panss . . . . . W106, T116  
 paralamina nucleus . . . . . W95  
 paraventricular nucleus of the thalamus . . . . . M25  
 Parental age . . . . . W87  
 Parkinson . . . . . W230  
 Parkinsonism . . . . . M5  
 partial agonist . . . . . W208  
 partner loss . . . . . M95  
 parvalbumin . . . . . T14, W177, T65  
 parvalbumin excitability . . . . . T34  
 pathological gambling . . . . . M143  
 pathway analysis . . . . . T28, T182, T192  
 pathways . . . . . W173

patient functioning . . . . . T111  
 Pavlovian . . . . . W237  
 PDE11 . . . . . W248  
 PDE4 . . . . . W200  
 pediatric . . . . . T90, T129, T167  
 Pediatric Acute-Onset Neuropsychiatric Syndrome . . . . . W163  
 pediatric PTSD . . . . . M126  
 pedunculo pontine tegmentum . . . . . M5  
 PENK polymorphism . . . . . M160  
 Pentraxin-3 . . . . . T259  
 perception . . . . . W55, W66  
 periaqueductal grey (PAG) . . . . . M37  
 Perinatal stress . . . . . M199  
 Perineuronal nets . . . . . T65, T14  
 peripheral blood mononuclear cells . . . . . W260  
 perirhinal cortex . . . . . W58  
 PET . . . . . W120, M118, M132, M145, M150,  
 M165, M180, M230, W61, W111,  
 W120, W123, W162  
 PET Resting Metabolism . . . . . M242  
 PET study . . . . . W153  
 PFC . . . . . T7  
 Pharmacodynamics . . . . . T242  
 pharmacogenetics . . . . . T152, T188, T189, T206, T254, T209  
 pharmacogenomics . . . . . T210, W159  
 Pharmacokinetics . . . . . T242  
 Pharmacology . . . . . M269, W194  
 pharmacotherapy . . . . . M243, T92  
 Phase I . . . . . W153  
 Phase III trial . . . . . W3  
 Phenotypes . . . . . T159  
 pHMRI . . . . . W128  
 phosphatase . . . . . T6  
 physical activity . . . . . W240  
 PKMzeta . . . . . M17  
 Placebo Response . . . . . T103  
 plasticity . . . . . T13, W231, M251  
 platform . . . . . T215  
 Poly IC . . . . . M49  
 polygenic risk score . . . . . M245, T186, T199  
 Positive Symptom Factor . . . . . T116  
 Positron emission tomography . . . . . M153, M143, M113, M136,  
 M157, M191, M237, W145  
 post-mortem . . . . . T193, T266, T22, T266, W108,  
 W177, W117, W118  
 Postmortem Brain Tissue . . . . . T233  
 postmortem human brain . . . . . M96  
 postpartum . . . . . M99, M117, M261, W102  
 postpartum depression . . . . . M154

- Posttraumatic stress disorder . . . . . T99, M253, M203  
 poverty . . . . . M172  
 pragmatic analysis . . . . . T110  
 prairie voles . . . . . M95  
 prazosin . . . . . T136  
 pre-school children . . . . . T195  
 precuneus . . . . . W33  
 prediction . . . . . M179  
 Predictive Models . . . . . T221  
 Predictive validity . . . . . W62  
 predictor . . . . . T131, W135  
 predictors of response . . . . . T252  
 Preferring . . . . . W204  
 prefrontal cortex . . . . . W264, M13, M29, M44, M54,  
     M88, M148, M185, M203, M238,  
     W21, W103, W107, W183, W227,  
     W233, W243, W249, W264,  
     M210, W104, W262, T67, T220  
 pregnancy . . . . . T149, W102, T249, T250, W169  
 prelimbic . . . . . W256  
 Prematurity . . . . . W53  
 prenatal . . . . . M129  
 prenatal stress . . . . . M60  
 Prepulse Inhibition . . . . . M103, M5, T204  
 Prepulse startle response . . . . . T201  
 Prescription drug abuse . . . . . W174  
 Prescription Opioids . . . . . T249  
 Prescriptions . . . . . W93  
 Preterm . . . . . M194  
 preterm birth . . . . . T149  
 prevalence . . . . . W86  
 prevention . . . . . T77, T226, T122  
 Prevention of Alzheimer's disease . . . . . T133  
 priming . . . . . W208  
 prodrome . . . . . W69  
 Professional Patient . . . . . T75  
 Professional subject . . . . . T75  
 progesterone . . . . . M99  
 Propensity scores . . . . . T219  
 Proteomics . . . . . T233, T215  
 proton magnetic resonance spectroscopy . . . . . W28  
 PSD-95 . . . . . T28  
 Psilocybin . . . . . W165  
 Psychiatric Comorbidity . . . . . W91  
 psychiatry . . . . . W167, M149  
 psychological distress . . . . . W81  
 psychometabolomics . . . . . W152  
 Psychoneuroimmunology . . . . . M227  
 psychophysiology . . . . . T117, T251  
 psychosis . . . . . W86, M22, M81, M90, M104, M115,  
     M137, M138, M191, M236, T184, W43,  
     W69, W71, W77, W86, W111, M106,  
     M119, M241, M251, T209, W66, W242  
 psychosis risk . . . . . M186  
 Psychostimulant . . . . . M30  
 Psychotherapy . . . . . W136, W141  
 Psychotic Disorders . . . . . T199  
 PTSD . . . . . T194, M19, M31, M113, M114, M178,  
     M189, M227, M242, T117, T126, T136,  
     T146, T164, T194, T200, T268, W23,  
     W34, W41, W65, W85  
 Publications . . . . . W167  
 punishment . . . . . M205  
 pupillometry . . . . . W46  
 PVH . . . . . T3
- Q**
- QTL . . . . . W101  
 Quality of Life . . . . . W91  
 Quantitative EEG . . . . . T96  
 Quantitative Electroencephalography (qEEG) . . . . . T128  
 quantitative trait locus . . . . . W96  
 Quetiapine . . . . . T120, T239
- R**
- R-fmri . . . . . T89  
 racial/ethnic minority elderly . . . . . T226  
 raclopride . . . . . T155  
 raloxifene . . . . . T72  
 randomized clinical trial . . . . . T97  
 rapamycin . . . . . M15  
 Raphé . . . . . W122, T26  
 rare variation . . . . . T165  
 rat . . . . . M80  
 reappraisal . . . . . M148, W74  
 Receptor . . . . . M12, M266  
 receptor tyrosine kinase . . . . . T6  
 recollection and familiarity . . . . . W83  
 Recovery . . . . . M142, M55, T144  
 Recovery Definition . . . . . W164  
 Recurrence risk . . . . . W87  
 Regeneration . . . . . T55  
 regenerative therapy . . . . . T4  
 registry . . . . . T77, T250  
 reinforcement . . . . . M63  
 Reinforcement learning . . . . . M133





- serotonin 1a receptor . . . . . T193  
serotonin 2 receptor . . . . . T61  
serotonin 2A . . . . . W196  
Serotonin 5-HT<sub>2C</sub> Receptor . . . . . T29  
serotonin and norepinephrine reuptake inhibitor . . . . . T80,  
T107  
serotonin receptor . . . . . M9, M90  
serotonin reuptake inhibitors . . . . . T151  
Serotonin Transporter . . . . . W215, M42, M237  
SERT . . . . . T31  
sex difference . . . . . M254, M7, T269, T265  
sex-specific . . . . . T268  
Sexual Dimorphism . . . . . M221  
sexual dysfunction . . . . . M27  
Shati/Nat8l . . . . . W97  
sigma-1 receptor . . . . . W229  
sign-tracking . . . . . M25, W263  
Signal Detection Theory . . . . . W68  
simvastatin . . . . . T98  
sleep . . . . . M4, M35, M74, W139, W35, W245  
sleep disturbance . . . . . W113  
slow waves . . . . . M4  
Smoking . . . . . T78, M129, T243, W20, W88, W197  
Smoking Cessation . . . . . T81, T197  
SNP . . . . . M78  
SNP rs4680 . . . . . W64  
sociability . . . . . W188, W207  
social . . . . . M135, M239  
social anxiety . . . . . M177  
Social Behavior . . . . . M229, W195  
social cognition . . . . . T124, W19, W36, W72, M20, M20, T222,  
W39, W47  
Social Competence . . . . . T222  
social defeat . . . . . M35, T49  
Social defeat stress . . . . . M8, W221, M58, M71, T63, W221  
Social Deficits . . . . . T222  
social impairment . . . . . M171, W90  
social interaction . . . . . T260, W216, W253  
social learning . . . . . M62, W65  
social neuroscience . . . . . W26  
social perception . . . . . T261  
Social Phobia . . . . . W63  
Social stimuli . . . . . T251  
social stress . . . . . M57, T24, T245  
social withdrawal . . . . . W97  
soldiers . . . . . T136  
Soluble Epoxide Hydrolase . . . . . T51  
Somatostatin . . . . . W104  
Sonic Hedgehog . . . . . T20  
sorting nexin . . . . . T25  
Source Localization . . . . . M182  
Spatial Navigation . . . . . M20, M20  
SPECT . . . . . M197  
spine morphogenesis . . . . . T25  
spines . . . . . T12  
spontaneously hypertensive rat . . . . . M88  
SSRI . . . . . T58, T252, W159  
Startle . . . . . W23, W69  
state . . . . . W161  
stereotypy . . . . . T33  
stimulant . . . . . M204, T151  
stimulation . . . . . T112  
stratification . . . . . M130  
stress . . . . . M18, M24, M35, M51, M86, M92,  
M114, M135, M254, M263, T42,  
T56, T225, T237, W13, W176, W183,  
W244, W254, W256, M7, M19,  
M108, T263  
stress response circuitry . . . . . M138  
Striatal cortical circuits . . . . . W252  
striatum . . . . . M192, M124, M192, M202, M205,  
M252, T33, T229, W15, W32,  
W162, W259, W266, M98,  
M166, M200, W262  
Structural MRI . . . . . M109, M126  
structure-function . . . . . T8  
STS . . . . . W47  
Subclinical psychosis . . . . . M131  
subgenual . . . . . M260, W18  
Subjective Cognitive Impairment . . . . . T133  
subjective effects . . . . . T262  
Substance abuse . . . . . M150, M249, T173  
substance use disorder . . . . . W96  
Substance-related disorders . . . . . T219, W178  
subtypes . . . . . W267  
subventricular zone . . . . . T60  
suicide . . . . . M225, M255, T170, T191, T211,  
W228, W171, T139, W39, W85,  
W109, W170, W171  
Suicide Assessment . . . . . W170  
suicide behavior severity . . . . . T182  
symptoms . . . . . T125  
synapses . . . . . T43  
synaptic organizer . . . . . T8  
Synaptic Plasticity . . . . . M3, T47  
synaptic pruning . . . . . W245  
Synchronized Transcranial Magnetic Stimulation (sTMS)  
. . . . . T128  
systemic inflammation . . . . . W113  
systems biology . . . . . T166

## T

tau . . . . . M145  
 TDCS . . . . . T89  
 telomere . . . . . T46, W176, W244  
 testosterone . . . . . M255, M256  
 tetrahydrobiopterin . . . . . W152  
 Thalamus . . . . . M239, W122  
 THC . . . . . W190, W223  
 Threat Conditioning . . . . . W210  
 threat faces . . . . . M177  
 Tic disorders . . . . . W87, W163, T129  
 Tobacco . . . . . W120  
 Tobacco Smoking . . . . . T153  
 tolcapone . . . . . W64  
 Tolerability . . . . . W4  
 tolerance . . . . . W190  
 touchscreen . . . . . W220  
 Tourette syndrome . . . . . T129, T165  
 tractography . . . . . W150  
 trafficking . . . . . T48  
 Training . . . . . M270, T270  
 trait . . . . . M246  
 trait anger . . . . . M211  
 Trajectories . . . . . W85  
 transcranial direct current stimulation . . . . . W134  
 transcranial magnetic stimulation . . . . . W80, W105  
 transcription . . . . . W177  
 transcription factor . . . . . T7, T52  
 Transcriptome . . . . . T55, T166  
 transgenerational . . . . . M41  
 translation . . . . . T87  
 translational . . . . . T61, W218  
 Translational research . . . . . W62  
 translocator protein . . . . . M157  
 transporter occupancy . . . . . T252  
 Transporters . . . . . W269, W188  
 trauma . . . . . W41, W171, W169, W171, T147  
 Traumatic Memories . . . . . W210  
 Traumatic stress . . . . . M34  
 Treatment . . . . . M214, T121, T139, W199  
 Treatment Acceptability . . . . . T151  
 Treatment Domains . . . . . T239  
 treatment outcome . . . . . M179  
 treatment outcome prediction . . . . . T117  
 treatment resistance . . . . . M65, W135, T221  
 treatment resistant . . . . . T112, T115

Treatment Resistant Depression . . . . . T142, T190, T240  
 trichotillomania . . . . . W11  
 triple reuptake inhibitor . . . . . T94  
 TSPO . . . . . M196  
 TSPO and [11C]PBR-28 PET . . . . . M264  
 TSST . . . . . T160  
 tuberous sclerosis complex . . . . . M15

## U

Ulcerative Colitis . . . . . M268  
 uptake 2 . . . . . W188  
 Usage . . . . . W93

## V

vagus . . . . . W255  
 validity . . . . . T73  
 valproic acid . . . . . W202  
 Varenicline . . . . . M3, T81  
 vascular . . . . . M163  
 vasopressin . . . . . T124  
 VBM . . . . . W72  
 Venlafaxine . . . . . M174  
 ventral hippocampus . . . . . W246  
 Ventral Pallidum . . . . . W234  
 Ventral Striatum . . . . . M132  
 Ventral Tegmental Area . . . . . M89, T29, W257  
 Ventral tegmental area (VTA) . . . . . W233  
 Vestibular stimulation . . . . . W149  
 veterans . . . . . T126, W121  
 vilazodone . . . . . M27, T82  
 violence . . . . . T191  
 virtual reality . . . . . T218  
 visceral obesity . . . . . M258  
 Visual . . . . . W251  
 visual backward masking . . . . . W148  
 visual cortex . . . . . M116, W57  
 visual perception . . . . . W19  
 vmPFC . . . . . M126  
 voltammetry . . . . . W199  
 vortioxetine . . . . . W246, M155  
 voxel-based morphometry (VBM) . . . . . M37, M185  
 VR exposure therapy . . . . . T117  
 VTA . . . . . M18  
 Vulnerability . . . . . M170, W1

